Stockscreener 앱 받기
2.22
4.31%
-0.10
시간 외 거래:
2.22
전일 마감가:
$2.32
열려 있는:
$2.35
하루 거래량:
3.48M
Relative Volume:
0.51
시가총액:
$615.08M
수익:
-
순이익/손실:
$-225.14M
주가수익비율:
-1.1327
EPS:
-1.96
순현금흐름:
$-192.27M
1주 성능:
-6.72%
1개월 성능:
-5.53%
6개월 성능:
+180.30%
1년 성능:
+305.85%
1일 변동 폭
$2.21
$2.41
1주일 범위
$2.21
$2.59
52주 변동 폭
$0.3546
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
209 CHURCH STREET, NEW HAVEN
IVVD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
2.22 | 642.79M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-26 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 개시 | H.C. Wainwright | Buy |
모두보기
Invivyd Inc 주식(IVVD)의 최신 뉴스
Maverick Capital Ltd. Has $7.31 Million Position in Invivyd, Inc. $IVVD - MarketBeat
Invivyd (NASDAQ:IVVD) Trading Up 7%Still a Buy? - MarketBeat
Is Invivyd (IVVD) Using RSV Prophylaxis To Redefine Its Post‑COVID Strategy? - simplywall.st
Invivyd (IVVD) Is Down 8.6% After Advancing VBY329 For Pediatric RSV PreventionWhat's Changed - Yahoo Finance
What Analysts Think Is Changing The Story For Invivyd Now - Yahoo Finance
Will Invivyd Inc. stock deliver consistent dividendsWeekly Trend Recap & Daily Oversold Bounce Ideas - Newser
Invivyd (NASDAQ:IVVD) Shares Down 3.8%Here's Why - MarketBeat
Invivyd (NASDAQ:IVVD) Shares Gap UpWhat's Next? - MarketBeat
What catalysts could drive Invivyd Inc. stock higherQuarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
How Invivyd Inc. stock compares to industry benchmarksJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - Newser
A Look at Invivyd (IVVD) Valuation After Advancing VBY329 RSV Antibody Candidate into Preclinical Development - Yahoo Finance
What sentiment indicators say about Invivyd Inc. stockTrade Exit Summary & Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking - simplywall.st
Is Invivyd Inc. stock supported by strong fundamentalsTrade Analysis Summary & Weekly Sector Rotation Insights - moha.gov.vn
Could Invivyd's (IVVD) Pipeline Expansion Reveal a Shift in Its Long-Term Competitive Strategy? - simplywall.st
Invivyd Appoints New Director Amid Nasdaq Compliance - MSN
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
Invivyd Raises $117.2 Million in Public Offering - MSN
D. Boral Capital Downgrades Invivyd (IVVD) - MSN
Invivyd (NASDAQ:IVVD) Earns Hold Rating from D. Boral Capital - MarketBeat
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Invivyd (IVVD) Downgraded to Hold by D. Boral Capital | IVVD Sto - GuruFocus
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference - The Globe and Mail
Kevin McLaughlin Buys Handful Of Shares In Invivyd - simplywall.st
Invivyd (Nasdaq: IVVD) to Join 8th Annual Evercore Healthcare Conference Fireside Chat - Stock Titan
Invivyd nominates promising RSV antibody candidate for infants By Investing.com - Investing.com Australia
Invivyd Unveils Promising RSV Antibody Candidate - TipRanks
New Haven-based biotech firm nets $117M from public offering - Hartford Business Journal
Invivyd Selects Antibody Candidate for Respiratory Syncytial Virus Prevention - MarketScreener
Invivyd nominates promising RSV antibody candidate for infants - Investing.com
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness - The Manila Times
Invivyd, Inc. Advances VBY329 as Promising Monoclonal Antibody Candidate for RSV Prevention in Infants and Children - Quiver Quantitative
[8-K] Invivyd, Inc. Reports Material Event | IVVD SEC FilingForm 8-K - Stock Titan
Invivyd (Nasdaq: IVVD) picks RSV antibody VBY329, 1.5-fold potency, IND in 2026 - Stock Titan
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
What is the fair value of Invivyd Inc. stock nowIPO Watch & AI Driven Stock Reports - newser.com
Invivyd Stock Hits 19-Month High As Public Offering Lands Days After Point72, Janus Henderson Reveal Big Stakes - MSN
Invivyd Director Kevin F. McLaughlin Acquires 50,000 Shares - TradingView
Dir McLaughlin Buys 50,000 ($125K) Of Invivyd Inc [IVVD] - TradingView
[Form 4] Invivyd, Inc. Insider Trading Activity - Stock Titan
Candlestick signals on Invivyd Inc. stock todayTrade Exit Summary & Consistent Return Investment Signals - newser.com
Can Invivyd Inc. stock deliver surprise earnings beatQuarterly Risk Review & Daily Chart Pattern Signal Reports - newser.com
Invivyd announces proposed public offering of common stock - MSN
Is Invivyd Inc. stock vulnerable to regulatory risks2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Will Invivyd Inc. stock benefit from infrastructure spendingAnalyst Downgrade & Fast Entry and Exit Trade Plans - newser.com
Can Invivyd Inc. stock deliver consistent earnings growthWeekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Custom strategy builders for tracking Invivyd Inc.2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - newser.com
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):